Postmarketing surveillance study of nateglinide in Japan

Advances in Therapy

Volumn 22, Issue 5, 2005, Pages 513-526

  Taki, Hiroto ^a   Maki, Toshio ^a   Iso, Takako ^b   Iwamoto, Kenji ^b   Kajiura, Taiichi ^b  

^a AJINOMOTO CO INC   (Japan)

^b ASTELLAS PHARMA INC   (Japan)

Author keywords

Diabetes; Elderly; Hyperglycemia; Nateglinide; Obesity; Postmarketing surveillance study; Safety; Treatment efficacy

Indexed keywords

ALPHA GLUCOSIDASE INHIBITOR; BIGUANIDE DERIVATIVE; CHOLESTEROL; GLUCOSE; HEMOGLOBIN A1C; INSULIN; INSULIN SENSITIZING AGENT; NATEGLINIDE; SULFONYLUREA DERIVATIVE; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; COLD SWEAT; DIET RESTRICTION; DIZZINESS; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; ERYTHEMA MULTIFORME; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HUNGER; HYPOGLYCEMIA; JAPAN; KIDNEY DYSFUNCTION; LIVER DYSFUNCTION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; POSTPRANDIAL STATE; SYMPTOM; TRIACYLGLYCEROL BLOOD LEVEL;

BLOOD GLUCOSE; BODY MASS INDEX; CYCLOHEXANES; DIABETES MELLITUS, TYPE 2; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; JAPAN; LIPIDS; MALE; MIDDLE AGED; PHENYLALANINE; PRODUCT SURVEILLANCE, POSTMARKETING;

EID: 31144458077     PISSN: 0741238X     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02849871     Document Type: Article

References (12)

1. The DECODE Study Group. Glucose tolerance and mortality: comparison of WHO and American Diabetes Association diagnostic criteria. European Diabetes Epidemiology Group. Diabetes epidemiology: collaborative analysis of diagnostic criteria in Europe. Lancet. 1999;354:617-621.
2. Ceriello A. Postprandial hyperglycemia and diabetes complications. Is it time to treat? Diabetes. 2005;54:1-7.
3. Hanefeld M, Fischer S, Julius U, et al, for the DIS Group. Risk factors for myocardial infarction and death in newly detected NIDDM: the Diabetes Intervention Study, 11-year follow-up. Diabetologia. 1996;39:1577-1583.
4. Kannel WB, McGee DL. Diabetes and cardiovascular diseases: the Framingham Study. JAMA. 1979;241:2035-2038.
5. Ikenoue T, Akiyoshi M, Fujitani S. Hypoglycaemic and insulinotropic effects of a novel oral antidiabetic agent, (-)-N-(trans-4-isopropylcyclohexane- carbonyl)-D-phenylalanine (A-4166). Br J Pharmacol. 1997;120:137-145.
6. Kosaka K, Kikuchi M, Tarui S, et al. Phase-III study of a novel hypoglycemic agent, AY4166, on NIDDM patients in Japan (1): α-glucosidase inhibitor, voglibose-controlled multicenter double blind study. Yakuri Rinsho. 1997;7:699-727. [Japanese]
7. Hanefeld M, Bouter KP, Dickinson S, Guitard C. Rapid and short-acting mealtime insulin secretion with nateglinide. Diabetes Care. 2000;23:202-207.
8. Mine T, Miura K, Kitahara Y, Okano A, Kawamori R. Nateglinide suppresses postprandial hypertriglyceridemia in Zucker fatty rats and Goto-Kakizaki rats: comparison with voglibose and glibenclamide. Biol Pharma Bull. 2002;25:1412-1416.
9. Saloranta C, Hershon K, Ball M, Dickinson S, Holmes D. Efficacy and safety of nateglinide in type 2 diabetic patients with modest fasting hyperglycemia. J Clin Endocrinol Metab. 2002;87:4171-4176.
10. Kosaka K, Kikuchi M, Kuzuya K, et al. Effect of a novel hypoglycemic agent, AY4166, on postprandial blood glucose and pharmacokinetics of NIDDM patients. Yakuri Rinsho. 1997;7:653-668. [Japanese]
11. Uchino H, Niwa M, Shimizu T, et al. Impairment of early insulin response after glucose load, rather than insulin resistance, is responsible for postprandial hyperglycemia seen in obese type 2 diabetes: assessment using nateglinide, a new insulin secretagogue. Endocr J. 2000;47:639-641.
12. O'Moore-Sullivan TM, Prins JB. Thiazolidinediones and type 2 diabetes: new drugs for old disease [review]. Med J Aust. 2002;176:381-386.